Beyond not differing in terms of molecular features, HER2-low tumors do not appear to show clinically relevant differences in terms of prognosis compared with HER2-0 tumors, as observed in a large cohort study from our group (n = 5235)18 and in multiple similar studies17,19–29 Taken together, both molecular and prognostic studies suggest that HER2-low breast cancer does not represent a distinct molecular entity, but rather a heterogeneous group of tumors, whose biology and behavior is primarily dictated by HR expression. Here, HR is linked to breast cancer.